We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BODITECH

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. Its products include automatic ... read more Featured Products: More products

Download Mobile App




Novel Point-Of-Care Procalcitonin Assay Performance Analyzed

By LabMedica International staff writers
Posted on 11 Dec 2019
There is a growing use of procalcitonin (PCT) measurements as a mean to diagnose and manage sepsis and PCT emerged as a useful tool to manage it accordingly, particularly in the emergency department (ED) and intensive care units (ICU).

PCT has a fair diagnostic accuracy for bacteremia in adult, neonates, infants, and children, hospitalized patients suspected of infection or sepsis. More...
Low procalcitonin levels can be used to rule out the presence of bacteremia. All commercial quantitative assays use the same ‘sandwich enzyme-linked immunosorbent assay (ELISA) principle to quantify PCT by forming antibody–procalcitonin–antibody complexes.

Scientists connected with the Hospital Center Université de Montpellier (Montpellier, France) analyzed the performance of the AFIASPCT Plus assay that was conducted using the AFIAS-6 instrument (Boditech, Dongnae-myeon, Republic of Korea). The AFIAS PCT Plus assay is a fluorescence immunoassay that quantifies PCT concentration in serum, plasma and whole blood (10–50 μL) drawn from a finger or heel using a capillary tip. The AFIAS-6 point of care (POC) assay uses an all-in-one cartridge which automates the entire procedure from sample preparation to test. PCT levels were determined using the BRAHMS PCT assay (B·R·A·H·M·S GmbH, Hennigsdorf, Germany), which is routinely used at the central laboratory.

Analytical performances including imprecision studies, limit of blank (LoB), limit of detection (LoD) and limit of quantification (LOQ) were determined. The method comparison was performed using plasma versus whole blood for the BRAHMS Kryptor CompactPlus versus AFIAS-6, respectively. The scientists reported that the total imprecision was far from the coefficient of variation (CV) of 4.5% claimed by the manufacturer and close to 10%, for levels of PCT at 0.4 and 8.3 μg/L. The LoD of this novel PCT assay was found to close to the LoD provided by the manufacturer at 0.04 μg/L. The LOQ was higher than that claimed by the manufacturer (0.1 versus 0.002, respectively). Correlation studies showed a good correlation between PCT measurements using plasma on Kryptor system and on corresponding whole blood with POC reaching a bias of −0.04 in the range from 0.02 to 2 μg/L.

The authors concluded that the novel PCT assay on AFIAS-6 is an acceptable POC alternative for the diagnosis and management of sepsis at EDs to improve the flow of patients, as results are consistent with those of the standard PCT Kryptor Compact Plus assay, despite its higher imprecision. The study was available online since October 26, 2019 in the journal Practical Laboratory Medicine.

Related Links:
Hospital Center Université de Montpellier
Boditech
B·R·A·H·M·S GmbH



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.